Tag: CPH
Creso Pharma’s Halucenex expands phase II psilocybin trial to include non-veteran PTSD sufferers
Creso Pharma’s (ASX: CPH) Canadian acquisition target Halucenex Life Sciences has expanded the recruitment of a phase II clinical trial of psychedelic psilocybin to include non-veteran sufferers of tr...
Creso Pharma expands distribution agreement with Route 2 Pharm, eyes Latin American cannabis market
Creso Pharma (ASX: CPH) has expanded a distribution agreement with Route 2 Pharm Pvt Ltd that will see Creso’s hemp-based products sold in Ecuador as a starting point into the lucrative Latin American...
Creso Pharma and Halucenex expedite US market entry following proposed law to decriminalise psychedelic drugs
A proposed bill to decriminalise the possession and sharing of psychedelic drugs in California has seen Creso Pharma (ASX: CPH) and its acquisition target Halucenex expedite a market entry strategy fo...
Creso Pharma’s Canadian subsidiary Halucenex embarks on US market entry strategy
Creso Pharma’s (ASX: CPH) soon-to-be-subsidiary Halucenex Life Sciences Inc has inked a deal with US-based scientific consultancy HeteroGeneity LLC to progress a US market entry strategy for its range...
Creso Pharma finalises development of hemp-based feedstock to reduce tail biting in pig herds
Biotechnology company Creso Pharma (ASX: CPH) has finalised the development of a hemp-derived feedstock known as Anibidoil Swine to support stress reduction and wellbeing in pigs.
The Swiss-made fl...
Creso Pharma subsidiary Mernova granted craft designation for Ritual Green cannabis products
Creso Pharma’s (ASX: CPH) Canadian subsidiary Mernova Medicinal Inc has been awarded craft designation by the Ontario Cannabis Store (OCS) for its Ritual Green cannabis products.
Ritual Green is a ...
Creso Pharma’s Halucenex almost doubles synthetic psilocybin supply
Creso Pharma’s (ASX: CPH) soon-to-be subsidiary Halucenex Life Sciences has almost doubled its synthetic psilocybin supply as it gears up for a clinical trial and other research and development.
In...
Creso Pharma acquisition target Halucenex to test efficacy of synthetic liquid psilocybin for use in treatment-resistant PTSD
Creso Pharma's (ASX: CPH) acquisition target Halucenex Life Sciences Inc has signed an agreement with Canadian pharmaceutical research firm Nucro-Technics to provide microbiology and chemistry test wo...
Creso Pharma’s Halucenex makes deal to create pure psilocybin amid softening regulations
As California moves to decriminalise psychedelics, Creso Pharma’s (ASX: CPH) soon-to-be subsidiary Halucenex Life Sciences has signed a letter of intent with Canadian listed Sixth Wave Innovations to ...
Creso Pharma signs bilateral deal with South African skincare company to market cannabidoil products
Biotechnology company Creso Pharma (ASX: CPH) has signed a bilateral commercial agreement with South African skincare company Cannabis Queen to market and distribute its range of cannabidoil-based nut...
Creso Pharma acquisition target Halucenex joins forces with US biotech to explore the use of magic mushrooms in treating mental illness
Creso Pharma (ASX: CPH) target acquisition company Halucenex Life Sciences Inc has entered into an advisory agreement with US-based biotechnology firm Growing Together Research Inc (GTR) to explore th...
Creso Pharma subsidiary Mernova expands in Canada’s recreational cannabis market with more orders
Creso Pharma’s (ASX: CPH) Canadian subsidiary Mernova has collared further purchase orders that include its Ritual Sticks pre-rolled joints and new one-ounce bag offering, which are both part of the w...
Creso Pharma appoints new business director ahead of US legalisation for recreational cannabis
Australian company Creso Pharma (ASX: CPH) has appointed leading cannabis executive John Griese to the role of director of US business development, following a global trend towards cannabis legalisati...
Creso Pharma launches three CBD-based tea products under cannaQIX brand
As its entry into the psychedelic medicine space progresses, Creso Pharma (ASX: CPH) has continued its cannabinoid product focus with the launch of three CBD-based tea products.
The company has unv...
With their mind-blowing medical potential, are hallucinogens the next ASX ‘pot stock’ equivalent?
The mere mention of magic mushrooms, ecstasy or ketamine is enough to send parents of teenagers into conniptions. But are these so-called party drugs poised to follow cannabis into the realm of a medi...
Creso Pharma’s soon-to-be subsidiary Halucenex executes deal to generate psychedelic extracts in-house
Creso Pharma’s (ASX: CPH) soon to be subsidiary Halucenex Life Sciences will have access to high quality psychedelic extracts for its proposed research via an agreement with medical and recreational e...
Creso Pharma eyes OTCQB dual listing, acquisition target Halucenex secures more psilocybin to underpin PTSD trial
Ahead of its upcoming post traumatic stress disorder clinical trials, Creso Pharma’s (ASX: CPH) soon to be subsidiary Canadian psychedelic medicine focused Halucenex Life Sciences has secured pharmace...
Creso Pharma’s Canadian subsidiary Mernova continues sales growth after receiving three new purchase orders
Creso Pharma (ASX: CPH) has closed out a busy week with news its wholly-owned Canada-based subsidiary Mernova had received three purchase orders worth a combined $183,019.
The purchases include the...
Creso Pharma’s acquisition target Halucenex prepares for PTSD trials
Fresh from revealing its proposed acquisition of Canadian psychedelics company Halucenex, Creso Pharma (ASX: CPH) has announced the appointment of a lead investigator for its target’s phase two clinic...
Creso Pharma makes transformational deal to acquire Canadian psychedelics company Halucenex
Creso Pharma (ASX: CPH) has announced a transformational move to evolve from a medical cannabis company to an integrated natural medicines provider with the acquisition of Canadian psychedelics compan...
Creso Pharma expands into Canada’s largest recreational cannabis market amid softening regulatory environment
Medicinal cannabis company Creso Pharma (ASX: CPH) has been riding the wave of loosening regulations relating to cannabis, with company also revealing it has expanded into Canada’s largest recreationa...
